Zota Health Care: Monitoring Agency Report for Q1FY27 QIP Fund Utilization
Zota Health Care Limited's QIP Monitoring Agency Report for Q1FY27 shows ₹34,033.24 lakh in net proceeds. As of June 30, 2026, ₹7,676.24 lakh remained unutilized, primarily invested in fixed deposits. Funds were used for working capital, COCO store expansion via DHML, and general corporate purposes.
This is a routine disclosure regarding the utilization of previously raised funds. It does not introduce new financial information or strategic shifts that would significantly impact the company's valuation or operations.
The report is a routine monitoring agency submission detailing fund utilization. It confirms compliance with the QIP's stated objectives and does not contain any significantly positive or negative news.
Zota Health Care Limited has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. This report, issued by CRISIL Ratings Limited, details the utilization of funds raised through a Qualified Institutional Placement (QIP).
The QIP, approved by the Board and members in September 2025, raised ₹34,999.99 lakh (net proceeds of ₹34,033.24 lakh).
The funds were allocated for three main purposes: funding working capital requirements, investment in DHML for setting up new COCO stores, and general corporate purposes. As of June 30, 2026, ₹7,676.24 lakh remained unutilized out of the total net proceeds.
Specifically, ₹5,754.80 lakh was utilized for working capital, ₹1,005.67 lakh for investment in DHML (Davaindia Health Mart Limited) for COCO stores, and ₹915.77 lakh for general corporate purposes, including advance income tax, TDS payments, and investment in Davaindia Health Mart Limited.
The unutilized proceeds, amounting to ₹26,357.00 lakh, were primarily invested in fixed deposits with ICICI Bank, with maturity dates ranging from July 2026 to April 2027. The total earnings on these investments as of March 31, 2026, were ₹663.20 lakh.
The Audit Committee and Board of Directors reviewed the Monitoring Agency Report on August 13, 2026. The report confirms that the utilization of proceeds is in line with the disclosures made in the Offer Document, with no material deviations or requirement for shareholder approval for deviations.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.